Adeno-associated viral vectors for Parkinson's disease

International Review of Neurobiology

Volumn 55, Issue , 2003, Pages 205-222

  Muramatsu, Shin Ichi ^a   Wang, Lijun ^a   Ikeguchi, Kunihiko ^a   Fujimoto, Ken Ichi ^a   Nakano, Imaharu ^a   Okada, Takashi ^a   Mizukami, Hiroaki ^a   Hanazono, Yutaka ^a   Kume, Akihiro ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; METHODOLOGY; PARKINSON DISEASE; REVIEW;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; PARKINSON DISEASE;

EID: 19244367698     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(03)01009-2     Document Type: Article

References (63)

1. Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T. F., and Harvey-White, J. (2000). Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp. Neurol. 164, 2-14.
2. Bantel-Schaal, U., Delius, H., Schmidt, R., and zur Hausen, H. (1999). Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J. Virol. 73, 939-947.
3. Berns, K. I., Bergoin, M., Bloom, M., Lederman, M., Muzyczka, N., Siegl, G., Tal, J., and Tattersall, P. (1995). Family Parvoviridae. In "Virus Taxonomy. Classification and Nomenclature of Viruses" (F. A. Murphy et al., Ed.), pp. 169-178. Springer-Verlag, New York.
4. Bilang-Bleuel, A., Revah, F., Colin, P., Locquet, I., Robert, J. J., Mallet, J., and Horellou, P. (1997). Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA 94, 8818-8823.
5. Bjorklund, A., and Lindvall, O. (2000). Cell replacement therapies for central nervous system disorders. Nat. Neurosci. 3, 537-544.
6. Bjorldund, A., Kirik, D., Rosenblad, C., Georgievska, B., Lundberg, C., and Mandel, R. J. (2000). Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886, 82-98.
7. Bohn, M. C. (2000). Parkinson's disease: A neurodegenerative disease particularly amenable to gene therapy. Mol. Ther. 1, 494-496.
8. Brooks, D. J. (2000). Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J. Neurol. 247(Suppl. 2), II 11-18.
9. Carey, R. J., Pinheiro-Carrera, M., Dai, H., Tomaz, C., and Huston, J. P. (1995). L-DOPA and psychosis: Evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone. Biol. Pychiatry 38, 669-676.
10. Chiorini, J. A., Yang, L., Liu, Y., Safer, B., and Kotin, R. M. (1997). Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823-6833.
11. Chiorini, J. A., Kim, F., Yang, L., and Kotin, R. M. (1999). Cloning and characterization of adeno-associated virus type 5. J. Virol. 73, 1309-1319.
12. Choi-Lundberg, D. L., Lin, Q., Chang, Y. N., Chiang, Y. L., Hay, C. M., Mohajeri, H., Davidson, B. L., and Bohn, M. C. (1997). Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275, 838-841.
13. Choi-Lundberg, D. L., Lin, Q., Schallert, T., Crippens, D., Davidson, B. L., Chang, Y. N., Chiang, Y. L., Qjan, J., Bardwaj, L., and Bohn, M. C. (1998). Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp. Neurol. 154, 261-275.
14. Connor, B., Kozlowski, D. A., Schallert, T., Tillerson, J. L., Davidson, B. L., and Bohn, M. C. (1999). Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther. 6, 1936-1951.
15. Connor, B., Kozlowski, D. A., Unnerstall, J. R., Elsworth, J. D., Tillerson, J. L., Schallert, T., and Bohn, M. C. (2001). Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration. Exp. Neurol. 169, 83-95.
16. Du, B., Wu, P., Boldt-Houle, D. M., and Terwilliger, E. F. (1996). Efficient transduction of human neurons with an adeno-associated virus vector. Gene Ther. 3, 254-261.
17. Dunnett, S. B., and Bjorklund, A. (1999). Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399, A32-39.
18. During, M. J., Samulski, R. J., Elsworth, J. D., Kaplitt, M. G., Leone, P., Xiao, X., Li, J., Freese, A., Taylor, J. R., Roth, R. H., Sladek, J. R., Jr., O'Malley, K. L., and Redmond, D. E., Jr. (1998). In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther. 5, 820-827.
19. During, M. J., Kaplitt, M. G., Stern, M. B., and Eidelberg, D. (2001). Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum. Gene Ther. 12, 1589-1591.
20. Fan, D. S., Ogawa, M., Fujimoto, K. I., Ikeguchi, K., Ogasawara, Y., Urabe, M., Nishizawa, M., Nakano, I., Yoshida, M., Nagatsu, I., Ichinose, H., Nagatsu, T., Kurtzman, G. J., and Ozawa, K. (1998). Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene Ther. 9, 2527-2535.
21. Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnson, J., and Wilson, J. M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 11854-11859.
22. Grondin, R., and Gash, D. M. (1998). Glial cell line-derived neurotrophic factor (GDNF): A drug candidate for the treatment of Parkinson's disease. J. Neurol. 245, P35-42.
23. Hardy, J., Cookson, M. R., and Singleton, A. (2003). Genes and parkinsonism. Lancet Neurol. 2, 221-228.
24. High, K. A. (2001). AAV-mediated gene transfer for hemophilia. Ann. N.Y. Acad. Sci. 953, 64-74.
25. Hoshiga, M., Hatakeyama, K., Watanabe, M., Shimada, M., and Kagamiyama, H. (1993). Autoradiographic distribution of [14C]tetrahydrobiopterin and its developmental change in mice. J. Pharmacol. Exp. Ther. 267, 971-978.
26. Jenner, P. (2000). Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann. Neurol. 47, S90-99.
27. Kaddis, F. G., Clarkson, E. D., Weber, M. J., Vandenbergh, D. J., Donovan, D. M., Mallet, J., Horellou, P., Uhl, G. R., and Freed, C. R. (1997). Intrastriatal grafting of Cos cells stably expressing human aromatic L-amino acid decarboxylase: Neurochemical effects. J. Neurochem. 68, 1520-1526.
28. Kang, U. J., Lee, W. Y., and Chang, J. W. (2001). Gene therapy for Parkinson's disease: Determining the genes necessary for optimal dopamine replacement in rat models. Hum. Cell 14, 39-18.
29. Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'Malley, K. L., and During, M. J. (1994). Long-term gene expression and phenotypic correction using adeho-associated virus vectors in the mammalian brain. Nat. Genet. 8, 148-154.
30. Kaspar, B. K., Erickson, D., Schaffer, D., Hinh, L., Gage, F. H., and Peterson, D. A. (2002). Targeted retrograde gene delivery for neuronal protection. Mol. Ther. 5, 50-56.
31. Kirik, D., Rosenblad, C., Bjorklund, A., and Mandel, R. J. (2000). Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 20, 4686-4700.
32. Kirik, D., Georgievska, B., Burger, C., Winkler, C., Muzyczka, N., Mandel, R. J., and Bjorklund, A. (2002). Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc. Natl. Acad. Sci. USA 99, 4708-1713.
33. Klein, R. L., Lewis, M. H., Muzyczka, N., and Meyer, E. M. (1999). Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res. 847, 314-320.
34. Kordower, J. H., Palfi, S., Chen, E. Y., Ma, S. Y., Sendera, T., Cochran, E. J., Mufson, E. J., Penn, R., Goetz, C. G., and Comella, C. D. (1999). Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419-124.
35. Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E. Y., Palfi, S., Roitberg, B. Z., Brown, W. D., Holden, J. E., Pyzalski, R., Taylor, M. D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Deglon, N., and Aebischer, P. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773.
36. Kozlowski, D. A., Connor, B., Tillerson, J. L., Schallert, T., and Bohn, M. C. (2000). Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp. Neurol. 166, 1-15.
37. Lange, H., Thorner, G., Hopf, A., and Schroder, K. F. (1976). Morphometric studies of the neuropathological changes in choreatic diseases. J. Neurol. Sci. 8, 401-425.
38. Langston, J. W., Quik, M., Petzinger, G., Jakowec, M., and Di Monte, D. A. (2000). Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann. Neurol. 47, S79-89.
39. Leff, S. E., Spratt, S. K., Snyder, R. O., and Mandel, R. J. (1999). Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscicnce 92, 185-196.
40. Levine, R. A., Miller, L. P., and Lovenberg, W. (1981). Tetrahydrobiopetrin in striatum: localization in dopamine nerve terminals and role in catecholamine synthesis. Science 214, 919-921.
41. Lieberman, D. M., Laske, D. W., Morrison, P. F., Bankiewicz, K. S., and Oldfield, E. H. (1995). Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg. 82, 1021-1029.
42. Mandel, R. J., Spratt, S. K., Snyder, R. O., and Leff, S. E. (1997). Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. USA 94, 14083-14088.
43. Mandel, R. J., Rendahl, K. G., Spratt, S. K., Snyder, R. O., Cohen, L. K., and Leff, S. E. (1998). Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J. Neurosci. 18, 4271-1284.
44. Mandel, R. J., Snyder, R. O., and Leff, S. E. (1999). Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp. Neurol. 160, 205-214.
45. Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G. J., Iwaki, Y., and Colosi, P. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 5, 938-945.
46. Miller, D. G., Rutledge, E. A., and Russell, D. W. (2002). Chromosomal effects of adeno-associated virus vector integration. Nat. Genet. 30, 147-148.
47. Mochizuki, H., Hayakawa, H., Migita, M., Shibata, M., Tanaka, R., Suzuki, A., Shimo-Nakanishi, Y., Urabe, T., Yamada, M., Tamayose, K., Shimada, T., Miura, M., and Mizuno, Y. (2001). An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. USA 98, 10918-10923.
48. Muramatsu, S., Mizukami, H., Young, N. S., and Brown, K. E. (1996). Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 221, 208-217.
49. Muramatsu, S., Fujimoto, K., Ikeguchi, K., Shizuma, N., Kawasaki, K., Ono, F., Shen, Y., Wang, L., Mizukami, H., Kume, A., Matsumura, M., Nagatsu, I., Urano, F., Ichinose, H., Nagatsu, T., Terao, K., Nakano, I., and Ozawa, K. (2002). Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther. 13, 345-354.
50. Nagatsu, I., Arai, R., Sakai, M., Yamawaki, Y., Takeuchi, T., Karasawa, N., and Nagatsu, T. (1997). Immunohistochemical colocalization of GTP cyclohydrolase I in the nigrostriatal system with tyrosine hydroxylase. Neurosci. Lett. 224, 185-188.
51. Nagatsu, T., and Ichinose, H. (1999). Molecular biology of catecholamine-related enzymes in relation to Parkinson's disease. Cell. Mol. Neurobiol. 19, 57-66.
52. Nagatsu, T., Horikoshi, T., Sawada, M., Nagatsu, I., Kondo, T., Iizuka, R., and Narabayashi, H. (1987). Biosynthesis of tetrahydrobiopterin in parkinsonian human brain. Adv. Neurol. 45, 223-226.
53. Nakamura, K., Ahmed, M., Barr, E., Leiden, J. M., and Kang, U. J. (2000). The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models. Cell Transplant 9, 567-576.
54. Natsume, A., Mata, M., Goss, J., Huang, S., Wolfe, D., Oligino, T., Glorioso, J., and Fink, D. J. (2001). Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp. Neurol. 169, 231-238.
55. Rutledge, E. A., Halbert, C. L., and Russell, D. W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309-319.
56. Sanchez-Pernaute, R., Harvey-White, J., Cunningham, J., and Bankiewicz, K. S. (2001). Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid dccarboxylase into the striatum of 6-OHDA-lesioned rats. Mol. Ther. 4, 324-330.
57. Shen, Y., Muramatsu, S. I., Ikeguchi, K., Fujimoto, K. I., Fan, D. S., Ogawa, M., Mizukami, H., Urabe, M., Kume, A., Nagatsu, I., Urano, F., Suzuki, T., Ichinose, H., Nagatsu, T., Monahan, J., Nakano, I., and Ozawa, K. (2000). Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum. Gene Ther. 11, 1509-1519.
58. Srivastava, A., Lusby, E. W., and Berns, K. I. (1983). Nucleotide sequence and organization of the adeno-associated virus 2 genome. J. Virol. 45, 555-564.
59. Wachtel, S. R., Bencsics, C., and Kang, U. J. (1997). Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. J. Neurochem. 69, 2055-2063.
60. Walton, K. M. (1999). GDNF: A novel factor with therapeutic potential for neurodegenerative disorders. Mol. Neurobiol. 19, 43-59.
61. Wang, L., Muramatsu, S., Lu, Y., Ikeguchi, K., Fujimoto, K., Okada, T., Mizukami, H., Hanazono, Y., Kume, A., Urano, F., Ichinose, H., Nagatsu, T., Nakano, I., and Ozawa, K. (2002). Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther. 9, 381-389.
62. Xiao, W, Chirmule, N., Berta, S. C., McCullough, B., Gao, G., and Wilson, J. M. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73, 3994-4003.
63. Zhong, X. H., Haycock, J. W., Shannak, K., Robitaille, Y., Fratkin, J., Koeppen, A. H., Hornykiewicz, O., and Kish, S. J. (1995). Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy. Mov. Disord. 10, 10-17.